Sensible SEND Blog

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit

Are you ready for a tighter standard?

Marc Ellison

As work continues on the content and updates for SEND 4.0, there’s a definite change in approach in an effort to make study representation more uniform, and to give implementors much clearer direction.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionSENDSEND Advantage ServicesSensible SENDSubmit

How creative should we be with SEND?

Marc Ellison

Can a certain study or data type be represented in SEND? The more ‘creative’ we need to get to place data in SEND, then potentially the less useful it is.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SENDSubmit

SEND in 2023

Marc Ellison

What the year ahead looks like for the world of SEND.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSENDSEND Advantage ServicesSensible SEND

So, was SEND Sensible in 2022?

Marc Ellison

As 2022 ends, Marc reflects on SEND’s progress – from upcoming standards to spirited debates sparked by this blog.

BiotechCROPharmaceuticalPre-ClinicalRegulatory SubmissionRegulatory SubmissionsSafety PharmacologySENDSEND Advantage ServicesSensible SENDSubmit

Nervous System Tests and SEND: What’s going on?

Marc Ellison

As the nervous system data can be vital to the safety assessment, shouldn’t we include it in SEND?

Stay up to Date

Get expert tips, industry news, and fresh content delivered to your inbox.